Необходимо ли контролировать ритму больных ишемической болезнью сердца,имеющих сахарный диабет?
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Список литературы
1. Оганов Р.Г. Развитие профилактической кардиологии в России. Кардиоваск. тер. и проф. 2004; 3(3): 10–4.
2. Di Francesco D., Camm A. Heart rate Lowering by Specific and Selective If Current Inhibition with Ivabradin. Drugs 2004; 64(16): 1757–65.
3. Braman N. Morbidity in Cardiovascular Disorders; Impact of Reduced Heart Rate. J Cardiovasc Pharmacol Ther 2001; 6(4): 313–31.
4. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339: 489–97.
5. Malmberg K, Herlitz J, Hjalmarson A, Ruden L. Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infraction. Retrospective data from two large scale studies. Eur Heart J 1989; 10: 423–8.
6. Freemantle N, Cleland J, Young P et al. Beta blockade after myocardial infarction. Systematic review and regression analysis. BMJ 1999; 318: 1730–7.
7. Fox K, Ford I, Steg PG et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 6736(8): 61170–8.
8. Reil JC, Bohm M. BEAUTIFUL results – the slower, the better? Lancet 2008; 6736(8): 61172–1.
9. Фомин И.В., Валикулова Ф.Ю. Антиангинальный эффект длительного применения ивабрадина у больных ишемической болезнью сердца и сахарным диабетом. Кардиология. 2009; 3: 9–15.
10. Kempler P. Neuropathies / Pathomechanism, clinical presentation, diagnosis, therapy. Ed. P.Kempler. Springer, 2002.
11. Vinik AI: Diabetic neuropathy: pathogenesis and therapy. Am J Med 1999; 107: 17S–26S.
12. Niakan E, Harati Y, Rolak LA et al. Silent myocardial infarction and diabetic cardiovascular autonomic neuropathy. Arch Intern Med 1986; 146: 2229–30.
13. Poople-Wilson PA, Swedberg K, Cleland JG et al. for the COMET Investigators. Comparison of carvedilol or metoprolol in the Carvedilol European Trial (Comet): randomized Controlled trial. Lancet 2003; 362: 7–13.
14. Burger AJ, Weinrauch LA, D'Elia A et al. Effects of glycemic control on heart rate variability in type 1 diabetic patients with cardiac autonomic neuropathy. Diabetes 1997; 46(Suppl. 2): 31S–7S.
2. Di Francesco D., Camm A. Heart rate Lowering by Specific and Selective If Current Inhibition with Ivabradin. Drugs 2004; 64(16): 1757–65.
3. Braman N. Morbidity in Cardiovascular Disorders; Impact of Reduced Heart Rate. J Cardiovasc Pharmacol Ther 2001; 6(4): 313–31.
4. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339: 489–97.
5. Malmberg K, Herlitz J, Hjalmarson A, Ruden L. Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infraction. Retrospective data from two large scale studies. Eur Heart J 1989; 10: 423–8.
6. Freemantle N, Cleland J, Young P et al. Beta blockade after myocardial infarction. Systematic review and regression analysis. BMJ 1999; 318: 1730–7.
7. Fox K, Ford I, Steg PG et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 6736(8): 61170–8.
8. Reil JC, Bohm M. BEAUTIFUL results – the slower, the better? Lancet 2008; 6736(8): 61172–1.
9. Фомин И.В., Валикулова Ф.Ю. Антиангинальный эффект длительного применения ивабрадина у больных ишемической болезнью сердца и сахарным диабетом. Кардиология. 2009; 3: 9–15.
10. Kempler P. Neuropathies / Pathomechanism, clinical presentation, diagnosis, therapy. Ed. P.Kempler. Springer, 2002.
11. Vinik AI: Diabetic neuropathy: pathogenesis and therapy. Am J Med 1999; 107: 17S–26S.
12. Niakan E, Harati Y, Rolak LA et al. Silent myocardial infarction and diabetic cardiovascular autonomic neuropathy. Arch Intern Med 1986; 146: 2229–30.
13. Poople-Wilson PA, Swedberg K, Cleland JG et al. for the COMET Investigators. Comparison of carvedilol or metoprolol in the Carvedilol European Trial (Comet): randomized Controlled trial. Lancet 2003; 362: 7–13.
14. Burger AJ, Weinrauch LA, D'Elia A et al. Effects of glycemic control on heart rate variability in type 1 diabetic patients with cardiac autonomic neuropathy. Diabetes 1997; 46(Suppl. 2): 31S–7S.
Авторы
И.В.Фомин, Ф.Ю.Валикулова
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.